Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Cumali Efe; Hannes Hagström; Henriette Ytting; Rahima A Bhanji; Niklas F Müller; Qixia Wang; Tugrul Purnak; Luigi Muratori; Mårten Werner; Hanns-Ulrich Marschall; Paolo Muratori; Fulya Gunşar; Daniel Klintman; Albert Parés; Alexandra Heurgué-Berlot; Thomas D Schiano; Mustafa Cengiz; Michele May-Sien Tana; Xiong Ma; Aldo J Montano-Loza; Thomas Berg; Sumita Verma; Fin Stolze Larsen; Ersan Ozaslan; Michael A Heneghan; Eric M Yoshida; Staffan Wahlin

doi:10.1016/j.cgh.2017.06.001

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Cumali Efe, Hannes Hagström, Henriette Ytting, Rahima A Bhanji, Niklas F Müller, Qixia Wang, Tugrul Purnak, Luigi Muratori, Mårten Werner, Hanns-Ulrich Marschall, Paolo Muratori, Fulya Gunşar, Daniel Klintman, Albert Parés, Alexandra Heurgué-Berlot, Thomas D Schiano, Mustafa Cengiz, Michele May-Sien Tana, Xiong Ma, Aldo J Montano-LozaThomas Berg, Sumita Verma, Fin Stolze Larsen, Ersan Ozaslan, Michael A Heneghan, Eric M Yoshida, Staffan Wahlin

114 Citations (Scopus)

Abstract

BACKGROUND & AIMS: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.

METHODS: We performed a retrospective study of data (from 19 centers in Europe, the United States, Canada, and China) from 201 patients with AIH who received second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 months (range, 6-190 mo). Patients were categorized according to their response to SOC. Patients in group 1 (n = 108) had a complete response to the SOC, but were switched to second-line therapy as a result of side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 (n = 93) had not responded to SOC.

RESULTS: There was no significant difference in the proportion of patients with a complete response to MMF (69.4%) vs tacrolimus (72.5%) (P = .639). In group 1, MMF and tacrolimus maintained a biochemical remission in 91.9% and 94.1% of patients, respectively (P = .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5% vs 34%, respectively; P = .029) There were similar proportions of liver-related deaths or liver transplantation among patients given MMF (13.2%) vs tacrolimus (10.3%) (log-rank, P = .472). Ten patients receiving MMF (8.3%) and 10 patients receiving tacrolimus (12.5%) developed side effects that required therapy withdrawal.

CONCLUSIONS: Long-term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH. The agents were equally effective in previous complete responders who did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of previous nonresponder patients compared with MMF.

Original language	English
Journal	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Volume	15
Issue number	12
Pages (from-to)	1950-1956.e1
ISSN	1542-3565
DOIs	https://doi.org/10.1016/j.cgh.2017.06.001
Publication status	Published - 2017

Keywords

Journal Article

Access to Document

10.1016/j.cgh.2017.06.001

Cite this

Efe, C., Hagström, H., Ytting, H., Bhanji, R. A., Müller, N. F., Wang, Q., Purnak, T., Muratori, L., Werner, M., Marschall, H.-U., Muratori, P., Gunşar, F., Klintman, D., Parés, A., Heurgué-Berlot, A., Schiano, T. D., Cengiz, M., May-Sien Tana, M., Ma, X., ... Wahlin, S. (2017). Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 15(12), 1950-1956.e1. https://doi.org/10.1016/j.cgh.2017.06.001

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. / Efe, Cumali; Hagström, Hannes; Ytting, Henriette et al.
In: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Vol. 15, No. 12, 2017, p. 1950-1956.e1.

Research output: Contribution to journal › Journal article › Research › peer-review

Efe, C, Hagström, H, Ytting, H, Bhanji, RA, Müller, NF, Wang, Q, Purnak, T, Muratori, L, Werner, M, Marschall, H-U, Muratori, P, Gunşar, F, Klintman, D, Parés, A, Heurgué-Berlot, A, Schiano, TD, Cengiz, M, May-Sien Tana, M, Ma, X, Montano-Loza, AJ, Berg, T, Verma, S, Larsen, FS, Ozaslan, E, Heneghan, MA, Yoshida, EM & Wahlin, S 2017, 'Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis', Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol. 15, no. 12, pp. 1950-1956.e1. https://doi.org/10.1016/j.cgh.2017.06.001

Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q et al. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(12):1950-1956.e1. doi: 10.1016/j.cgh.2017.06.001

@article{cc2be9ebb77843c1956a2bf88f04327b,

title = "Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis",

abstract = "BACKGROUND \& AIMS: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20\% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.METHODS: We performed a retrospective study of data (from 19 centers in Europe, the United States, Canada, and China) from 201 patients with AIH who received second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 months (range, 6-190 mo). Patients were categorized according to their response to SOC. Patients in group 1 (n = 108) had a complete response to the SOC, but were switched to second-line therapy as a result of side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 (n = 93) had not responded to SOC.RESULTS: There was no significant difference in the proportion of patients with a complete response to MMF (69.4\%) vs tacrolimus (72.5\%) (P = .639). In group 1, MMF and tacrolimus maintained a biochemical remission in 91.9\% and 94.1\% of patients, respectively (P = .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5\% vs 34\%, respectively; P = .029) There were similar proportions of liver-related deaths or liver transplantation among patients given MMF (13.2\%) vs tacrolimus (10.3\%) (log-rank, P = .472). Ten patients receiving MMF (8.3\%) and 10 patients receiving tacrolimus (12.5\%) developed side effects that required therapy withdrawal.CONCLUSIONS: Long-term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH. The agents were equally effective in previous complete responders who did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of previous nonresponder patients compared with MMF.",

keywords = "Journal Article",

author = "Cumali Efe and Hannes Hagstr{\"o}m and Henriette Ytting and Bhanji, \{Rahima A\} and M{\"u}ller, \{Niklas F\} and Qixia Wang and Tugrul Purnak and Luigi Muratori and M{\aa}rten Werner and Hanns-Ulrich Marschall and Paolo Muratori and Fulya Gun{\c s}ar and Daniel Klintman and Albert Par{\'e}s and Alexandra Heurgu{\'e}-Berlot and Schiano, \{Thomas D\} and Mustafa Cengiz and \{May-Sien Tana\}, Michele and Xiong Ma and Montano-Loza, \{Aldo J\} and Thomas Berg and Sumita Verma and Larsen, \{Fin Stolze\} and Ersan Ozaslan and Heneghan, \{Michael A\} and Yoshida, \{Eric M\} and Staffan Wahlin",

year = "2017",

doi = "10.1016/j.cgh.2017.06.001",

language = "English",

volume = "15",

pages = "1950--1956.e1",

journal = "Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "12",

}

TY - JOUR

T1 - Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

AU - Efe, Cumali

AU - Hagström, Hannes

AU - Ytting, Henriette

AU - Bhanji, Rahima A

AU - Müller, Niklas F

AU - Wang, Qixia

AU - Purnak, Tugrul

AU - Muratori, Luigi

AU - Werner, Mårten

AU - Marschall, Hanns-Ulrich

AU - Muratori, Paolo

AU - Gunşar, Fulya

AU - Klintman, Daniel

AU - Parés, Albert

AU - Heurgué-Berlot, Alexandra

AU - Schiano, Thomas D

AU - Cengiz, Mustafa

AU - May-Sien Tana, Michele

AU - Ma, Xiong

AU - Montano-Loza, Aldo J

AU - Berg, Thomas

AU - Verma, Sumita

AU - Larsen, Fin Stolze

AU - Ozaslan, Ersan

AU - Heneghan, Michael A

AU - Yoshida, Eric M

AU - Wahlin, Staffan

PY - 2017

Y1 - 2017

N2 - BACKGROUND & AIMS: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.METHODS: We performed a retrospective study of data (from 19 centers in Europe, the United States, Canada, and China) from 201 patients with AIH who received second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 months (range, 6-190 mo). Patients were categorized according to their response to SOC. Patients in group 1 (n = 108) had a complete response to the SOC, but were switched to second-line therapy as a result of side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 (n = 93) had not responded to SOC.RESULTS: There was no significant difference in the proportion of patients with a complete response to MMF (69.4%) vs tacrolimus (72.5%) (P = .639). In group 1, MMF and tacrolimus maintained a biochemical remission in 91.9% and 94.1% of patients, respectively (P = .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5% vs 34%, respectively; P = .029) There were similar proportions of liver-related deaths or liver transplantation among patients given MMF (13.2%) vs tacrolimus (10.3%) (log-rank, P = .472). Ten patients receiving MMF (8.3%) and 10 patients receiving tacrolimus (12.5%) developed side effects that required therapy withdrawal.CONCLUSIONS: Long-term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH. The agents were equally effective in previous complete responders who did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of previous nonresponder patients compared with MMF.

AB - BACKGROUND & AIMS: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.METHODS: We performed a retrospective study of data (from 19 centers in Europe, the United States, Canada, and China) from 201 patients with AIH who received second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 months (range, 6-190 mo). Patients were categorized according to their response to SOC. Patients in group 1 (n = 108) had a complete response to the SOC, but were switched to second-line therapy as a result of side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 (n = 93) had not responded to SOC.RESULTS: There was no significant difference in the proportion of patients with a complete response to MMF (69.4%) vs tacrolimus (72.5%) (P = .639). In group 1, MMF and tacrolimus maintained a biochemical remission in 91.9% and 94.1% of patients, respectively (P = .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5% vs 34%, respectively; P = .029) There were similar proportions of liver-related deaths or liver transplantation among patients given MMF (13.2%) vs tacrolimus (10.3%) (log-rank, P = .472). Ten patients receiving MMF (8.3%) and 10 patients receiving tacrolimus (12.5%) developed side effects that required therapy withdrawal.CONCLUSIONS: Long-term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH. The agents were equally effective in previous complete responders who did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of previous nonresponder patients compared with MMF.

KW - Journal Article

UR - https://www.scopus.com/pages/publications/85029848036

U2 - 10.1016/j.cgh.2017.06.001

DO - 10.1016/j.cgh.2017.06.001

M3 - Journal article

C2 - 28603052

SN - 1542-3565

VL - 15

SP - 1950-1956.e1

JO - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

JF - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

IS - 12

ER -

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this